[
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "The targets of some antibodies are proteo-glycans. One such antibody binds MUC1, but only if the threonine within one of MUC1's repeat sequences, GSTA, carries a TN antigen, a monosacharide of N-acetylgalactosamine. \nUsing published tools, you start to put together a system to study this antibody. Your MUC1 construct carries a flag tag and is expressed on the surface of C1GALT1 KO HEK293t cells that strictly produce TN O-glycans.  You were able to show that the sugar is essential to the interaction by using inhibitory concentrations of GalNAc (500 mM), as GalNAc inhibits the antibody's ability to bind when compared to PBS controls. In addition to verifying the surface expression of MUC1, why is it essential to include the anti-flag antibody, and to which step should it be added?\n\n\nAnswer Choices:\nA. No need, controls are good\nB. Anti-flag should be added with the secondary antibodies. Its included to control for potential off-target effects of the 500 mM GalNAc.\nC. Anti-flag should be added with the primary antibodies. Its included to verify GalNAc has not altered surface expression of MUC1\nD. Anti-flag should be added with the primary antibodies. Its included to control for potential off-target effects of the 500 mM GalNAc. \nE. Anti-flag should be added with the secondary antibodies. Its included to verify GalNAc has not altered surface expression of MUC1"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762204648-RLdUpKZTHSyv5ofsnEeI",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"C. The anti-Flag is a primary antibody control added during the primary-antibody incubation to confirm that GalNAc treatment (or any experimental manipulation) hasn\u2019t changed cell-surface levels or accessibility of your Flag\u2011tagged MUC1. This distinguishes a true loss of glycan-dependent binding from loss/masking of the protein epitope or reduced surface expression.\",\"answer_letter\":\"C\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Assessing antibody selection**\n\nI need to choose the correct option and reason through it. It's crucial to verify the surface expression of MUC1 and understand when to include the anti-flag antibody. The approach involves adding it with primary antibodies to ensure it recognizes the flag epitope and confirms GalNAc treatment hasn't changed surface expression. My answer is C. \n\nI'll craft a concise explanation for JSON: the anti-flag primary antibody ensures detection independent of glycan dependencies and must bind during primary incubation before secondary detection.**Clarifying antibody roles**\n\nI need to mention that including the anti-flag antibody prevents false negatives that could result from reduced expression or loss of accessibility. It's important to note that anti-flag is a primary antibody and the secondary antibody is added later in the process. I\u2019ll ensure my explanation is concise. \n\nI\u2019ll prepare a JSON response that includes the answer field with the explanation and set the answer_letter to \"C.\" That way, it\u2019s clear and accurate for the user.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Assessing antibody selection**\n\nI need to choose the correct option and reason through it. It's crucial to verify the surface expression of MUC1 and understand when to include the anti-flag antibody. The approach involves adding it with primary antibodies to ensure it recognizes the flag epitope and confirms GalNAc treatment hasn't changed surface expression. My answer is C. \n\nI'll craft a concise explanation for JSON: the anti-flag primary antibody ensures detection independent of glycan dependencies and must bind during primary incubation before secondary detection.**Clarifying antibody roles**\n\nI need to mention that including the anti-flag antibody prevents false negatives that could result from reduced expression or loss of accessibility. It's important to note that anti-flag is a primary antibody and the secondary antibody is added later in the process. I\u2019ll ensure my explanation is concise. \n\nI\u2019ll prepare a JSON response that includes the answer field with the explanation and set the answer_letter to \"C.\" That way, it\u2019s clear and accurate for the user.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCRvvj3Eus-vI0BoeVGR2gysBP9ZufG2Qp8Mk75k0Wety-AaOvPGUO7O57xaRbwhGADFESxiW67gu6x_792La8l3URkJXNna8gf1lVgzN0GBCHfBNEMjdFRtvmUAwDwLEtaNX8OGr2x7jnP7CLoPAI-1J-811TsT4Jf5HT-dcHJbHYPI2so7rHEcgA8_VnF3OJ45Ko_yKSBnPSJV9bAPXa9kzbr7NSaxuR6bpl1yajXl84KvEZxR4D_7jtLnlq4-Q666v8eV8__W3WMh_7bIjnPHBTUOjuDpG478ANCuAzN234Df488sXJ_-s-1O2FQfLcoMSsIbxF3a5SwHHzfs8CE355DU2RXc2E6GPZcDZO4TYYLSnVjiOhZ46Af3SxkLy2vn3HtKlbXJjLoYraJgL2S6y87QqIWR5sDS5_EV3jy2-_xguc8ZsPp9HdNmuDxRv1nOM70nK7DVVUma4m5G7U8X7p6NHp5E-Hj72KxmP5aK2NcOeFzy61lL4SfqqBDiViFQ5b1ycqsQHbDFO-KgxR3IrmRmu8OFfVusmBO5iYLrDLJdHMq-wMK7_4pIx2lWhjKZYQQ21csmXvxkDeAgs0qcJCQkIx1ySeO-HWifXbBUt_KggzwNMVJKLUbISJh8Nq7KmS1TP0g6OXLYYvgTWHBeUpkT6FLAe-ZzyJFW6KL_sVuAAYvfrqcpY_6U6hC_5rhlxsSxvqnJydkYgcNIZ4Ks7ulwwgZ8n9DIFWL8jP3wb3WHCYrdNxYyjsOZ3QIUo_6nxoRvf-1adSItk7_bAabwLIRw_UdrNqM-Nd0B5e7C7wwiLKmMviEBVhL2xAvcVnv_tW3QLp6Vs5YgvKSZNbmR4Xng3vx78DwefVQzV8tssYDwbkUQgV629chzvNYvD6Ltz4ahvsuhS7gEqARTen_f9UT7NJw62D6qIbMKnqy27xLukntNo7flKbJZpN9tgIBTGDXZE78Xrg84UqzuLzJZ6GzjLrcHIHLyVI7Nb3RLMWsxEJvVmSiLhoaZATlrQOcYxdwcwhJIaPMMgbCPMUncSaRQ_1l80uUXC5ZpA8fAdjJaTYtVNoaCSIMPj2HoxqV3A900N0Jd9MLlTp35A7FaGFyxwVxgAMvtBwFb9EM9ZDXvO9BetjthjT3ztRr8bsl4wgFuTm3PJaEay5PeyxPaoAP-JWzZ7wbpgVwTIqUGrRIxnMjTIMbhjn19ezYt3SDG3ci0h148lQPYvc6OsFZYz9qQXEugBYfpfm1pZD0i9rIbdg9BMckD2047Fl4pPXZIWg5zecjixbcoFEs-m5_1lEtQWf9NkvVf2TYjAQwwbMyQyhSKQXwfco9cOKD9hdRluYHr1Iy_fLq3QyF__6vmtlLTH7hQjW5aD20OkM_n8845wldbNF7Y2an2r0FS3JPrVwQa-cSB79egt8HBCJ29VOnf1v0gWBXci9M_Xp5PYvS9ognovH-CVO3hz0KlMC8DFlVaJXTxXayer_PhnRBqmXHOQ1e3eIPGJYGSlJe_Y7EefjLksMwI1ZI3gXOo8uIjcJKyu0jaRHtcSXU6_5yUonxZRzG6IhfOwvM0Wm2_loqsHeYaAT2m_yGOxdqq_YK5AJs0_puaz7A5viF2Tsc-7p2oxZ030qLFNTHsYVz4hjw-nvKbNawuD2I7gX0kbdY8VDpW7HilJapSFs6XtbDu-Kn-RqB59aZBc89IK16IpoRz8Zdt8W3f2L_i8RwOqSPTFpwdO9qc4VqxGP_uCmFT03u5L1JJfKQHzGoK8ygVrdqC2XPSUdpNIWSSPfr9lO06ppd3QQc6NFC7e6_ib84bbdqmo8muvl472uDp9cGOl8h700eXTUHLM_Arywage9jRaWdq_5N9skLtKlKtdCaWG7sR7K6-s98NS3DOQCkTG8iMge0UwloknH7eZOdvIkxg07brKZ6uPVNo6YVIL8YMTu_jEG4zmIe9f8tq47kSU8Kn0gOdJFg_nkzjEmv5N2SmVkILoUI5ZmH-Ufk8asN3nu9pqhXfd5unmW5per0ELBI1mP4VIo9_Bp2hjha0-oounRmbDHyVJVVNT5h7ek62I2SqZd2dZRZcE3mMq63ofP_as-Xc3Gl83DHZ_sonnGpGXcNY3fYeYNGw1odg1G73SwHbYb0G9NMyXRpSvxf8IfH8WA8bp7_bwrCczobT-kXcGt7n9U9MYi1zChqydwGrM95JIznyasZRRVzw8EvuOPtiYX5YScxYq3WP5L7vG_uN_Ul7PxHfpLB00LjhHId9B4fPzzrLSavw8KuVQE5i_MlI1BC9ALbmuspaus6q_D9tM5JXZRmBau0l-_xFw1R9Ls15-cgjPYddmtEOnwRkL5Yhlu6-PjgQnDhrSospyA9R_AoGCG8cV7pQ2_LihObdB_0uYFfXk-MJCqT9uDLxm0BLeuVkEMXnnknsww03nwbUa7IOIzJ7ZZ2HlvauXPPE1MaMvlNRPtxqsh7GIwfAJORxn93uXrTJxkoOQWbKABzcZC8g_Zgfi3bRZ63bApp2n3w==",
                "id": "rs_095b4c543ef4ce810169091be986908196b3bb0dd3df662b2e",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762204648,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 284,
        "prompt_tokens": 375,
        "total_tokens": 659,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 192,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00066175,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 9.375e-05,
          "upstream_inference_completions_cost": 0.000568
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "The targets of some antibodies are proteo-glycans. One such antibody binds MUC1, but only if the threonine within one of MUC1's repeat sequences, GSTA, carries a TN antigen, a monosacharide of N-acetylgalactosamine. \nUsing published tools, you start to put together a system to study this antibody. Your MUC1 construct carries a flag tag and is expressed on the surface of C1GALT1 KO HEK293t cells that strictly produce TN O-glycans.  You were able to show that the sugar is essential to the interaction by using inhibitory concentrations of GalNAc (500 mM), as GalNAc inhibits the antibody's ability to bind when compared to PBS controls. In addition to verifying the surface expression of MUC1, why is it essential to include the anti-flag antibody, and to which step should it be added?\n\n\nAnswer Choices:\nA. No need, controls are good\nB. Anti-flag should be added with the secondary antibodies. Its included to control for potential off-target effects of the 500 mM GalNAc.\nC. Anti-flag should be added with the primary antibodies. Its included to verify GalNAc has not altered surface expression of MUC1\nD. Anti-flag should be added with the primary antibodies. Its included to control for potential off-target effects of the 500 mM GalNAc. \nE. Anti-flag should be added with the secondary antibodies. Its included to verify GalNAc has not altered surface expression of MUC1"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762204648-cq4o7psRogjoOyP5q8No",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"C. The anti\u2011FLAG is a primary antibody used to detect the FLAG epitope on surface MUC1 and must be added during the primary antibody incubation. It provides a control showing that 500 mM GalNAc did not reduce or alter surface expression/localization of the FLAG\u2011tagged MUC1 (so loss of signal with the glycan\u2011dependent antibody is due to glycan blocking, not loss of antigen).\",\"answer_letter\":\"C\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": null,
            "reasoning_details": [
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCRvvs_1M5ERTwLRAhzTwUAPFBCJkZGUlic-lCgfbFD2cQipfoa8hw0r4S7hP-2y-LqGsczmrnfZv5iOiL7kZ6WD8LYRChM-qWupz0F3s7u2j3G2-W7DEg1gEpkw1e2j6NfnESywstGRcabrgVoMw4SayTxPO4bl4HrwG5fiASMjo0guiGfxUkc7Ia6FEt4dwLYGZFtRNcrD215PvZV15BfW7YAPFMrxz5LBUxmD5IrNFlYNg61MLB3f3Lx-NfQQith0N49DfbGSXMxIUvZAeksj4nrfFXaRGzBPPCPDu7TzteqO9GqJ3IErsiS3OiGRvib4ezpglPmjsLVNjmswUTb5Im_a04LUUNTSdr4tos1RTKKK0C8Hhs7OCM6_KOno6igg-Dn95w4vb4xsUqkyyxIKLz9W2BOd2hbMXCFCJor7rxbHkD9911UTSQXME4kjcZ9RwO3uRGn1mMguSJIERTQKuaqqp0R1DROX0NJ_76lx0HzibyG_rxPgDN9kUIXuTdcLXJeM1krah6YOeF1L8XBmTRB9pZxvvIapERV8_5tWmjNW9B4WM9_tzRM-NsUZJnLrNO5Ep2dA_SzXtvOr-m6CPHVTqEl3_7svXijZgffcU83CQCcRCLdceIYv1qFbzo7dzEqqgzTkEud_n5rUxi2zvmttXuZFyYRw6RLdrOeY6KUwPq4Ki7FWxgoVqIHxUvDzFUSRK9xfHOcJmfkGHzdZKsqoL37fcd36lXgZ_E7Fkw0Ue_UBBg1m2qKOzw1PWJRwwp1dlC6IQMuRW6AzK7wvE0_YLFgDje3kfTISHK5MtrYhZ8pvWZ89VEcCe_qdIPzyg87-wsXSzYO4HCVucFPkJTEgdDng5G4_joVULQSab7JY-JwvL5RjrdbKxxUJ6S2I4DCx_aNrKkX6m_z2bShT9OFI92c0tD5i1_4Z7Sjl8ppbNqufvyqsBGxb37wp8_jTRuxETsmI-kcMb1VxMdn59tOKtkYL0F2njlc5uYUuUJfYybwjD0HY4xtV67wzNA_w-IcAuR3Juqc__xf3WpINueChN-CrpGcLs-VNQgwb0MLhF-t4jpLDwC918aUdXlZYUP5MwKFx50PKFkqk1PUNzA9F8vRh3G7bvwvroBnaMTVW3yix5Vt_sU28Y5qm29lcDyj7Jb9ZO8hFG7GTf3LaBWqXjGg8yEqScaoF7AOvb1ajLFJM-rQOybdjQijE7D9u8qMJIx9bTlNJWPdYCBICqahL8pdDTXzgrExGDJXItzNYx4CnTWVtGfzVVIpybAF3Kuh0423YH6bV36_L9hZcvRjJJODfGHuRm-0L3IY9tcdgMt_G1r2m0W_rlPz2YTjotvev628rVONZtusRSGRqTscmMdYPwYcnk3pf_V8lHMdGRturpwQmzsG3BTQTFbZs8GuiyscsdTthWA54aNGMYIq2R1RQG2Dvew173JQ2BjKVUzNKW76tPX1PBxktZzCLc7t8Z23bXf52m0zl6i8Xs82_Yce3ummeJE0ZeCJUbM7woqr2MtDHyKEgxrGnQHU-ol_VbMfe9iu8cM1clDxmfshpfswACf_Ie_40bYv3XzUarfu5P45hVM62_b0fu4B6TC-UlZRtgnrqcFqwj1PhsGEZXQgr60MT-EqGLxXXmaJlcxHsBJzIE3M1SvrIjBsht6hNZwCACKv69zGnRoJrUwaaH2-e7B4dznlm8YKHoQ309Ysqbhz2sJpPl8aq-Zl7EyWiS_NAHrrjwXI8H4MBJ298mKuZKoclDud2aLq3rcpzTZfKx9Rrg9UXUaE5Jq5pm5jPzrE7dLIjJBkwILdmUY5V8d6buFG-b_kA38whKaNmL8QWVwXNq5ucx6ZTLKHPuUpXldHdRjmPtIJ_cqlqcIka_zMeMC5KJjVDG4WIhfYAaTuaIHYOfr11d0F72oSbiRqP3biJlYeBYhI9JXg4iAVJsjCYo5Co0wtnjmGg9ZPBBM3Ptmw6iYQexCU9-4cyj1lYotVh0PnZuAVmBfigHRdpjsEeIuS8xxMU3ApUzz456OFsV4aSdMKcKUyGz-C2rLj_H1UsIzQ5FHT2VNOJNU39Kw_GbkNSuvgvbXCyKq8jpO93t_lfkqnQA9tJh1AhBaJPYk33R7wVUu6fyPHbkS2S3kROGW2CcX3ygyGn681WQXpGYhSRo9OAclvINBvSaRe0luqp00b920UHmdyolmyr-PYUEvgYgqLFxyOtHU_5sESKV0iR_i-RURnO-vBpwm_R8URFXi4OoYfpVQxe3msTuYm_uRIjlZ_FEiUaKF1epYZ3QPQ3CPmd3x5R0ZbRqqEZDl0-S9WylXlBN7bVd-uvtYNm9aW7x4tGd135oVPicX_Q0uiAUpQ2ZpGWwXISMMUdnrAMFTWQhWoEefjFjpP9jqM80m-RyD-PgsKFnt-E6WAseZv1vn5hKiegQgsRzInk8iC6y5cfQIpJ4V2lEE2E7aLwg5WCnJyys8szRFBcf_6eITNe9KNrKqbK5Sd_FZxjqguBHTxwGcn1M0WYBCIYDZ_sATEHJYjmtFc3LeqALX-0GaLLMMME1j5pxUC5oAgvd47ji_BzRcP9AeMxC1j_G2o_a0VFi0DTGUsz-K25OQwS_BFaqE-8J8NAu5VQJfZuTLetaUjmd75l2f-8mG1SJwkITJjlmbtihEp4slQU-Gs2bVELBHKt3fggA-U1jNlRxsw6BO6ntHsEoMOpqhyxXtMpF9q0MVhZIZoPB0J5Wjljh_Oh4U6WA_szoSpLyNAm8pw8yldnT5UPtLaTErc5Dex3Y_AVhj-M6HpA0IxaAnXqSsE8P8NYoQqgFGEXqg2R1IMCnfiEIoclGtt5t7zIvg84D0upVTg8f5adEn6MNibgK6GsUaTzMGVB8Iugi_VDtdbMvxVL7ZqJ54iojgzwxkKAEavLMHed1iTuRyKGktFfY09pC1nG-57uVT8ns7OBqm7zQXLQAk8xlN9ugmU-qJPgKdK061tbB6eAE3bGAPcTy5upN8w5WONWEkn1RatnZYQ4VWAeP9SOPUDsQdA_G_I3BzMRaXXxdo0292eWycloWWh0MlWDsyo4J7Eni8jX4j9wwyx_eP7lnomLyQRxTKETWV9owI7pIxJT0-O0VQmlkq6gm947ehJ8QgqLzjqzQ4V3hKq1V4DIssUFDLg02ZhOKrYz1G3_b7yiQYMDybAvR6isWUwFGq4FnV1LAZs3_BFfX1xlVHQKtCV3tRQ4caWo7QMnwCHK37cuKAeUkyRNy0vxdu81iK6JVJs2t8y8VcmPfY4NPutnMNkbxlsqB0USTp6NfZzpSAlfiQ9woMifaq_d9K8d4je5thgHTkteXNVDd0Su7hPn9B9Emmmit6Jfmt-siRdtHGn8QJ3i8P7hfD_kUrluqk11rhBYG5Wuoha9qGvL5TT7wzaCnsZ20k6rB6nuji4QWif7A1VtZ2Ltyr6Supicuy1zw1rzcNyBoY4votfPZLHHRmg5oKJIyVU3hjcM7JmU2sVO4cd130XUAceru4-WIrG6CCmMATcAhBT4OdfGT-cvtCTdcnKKKoL7hbPDUf0MWOykfVd0AERfHviYaARmP4H1n4l8y1IZTGyghC6XcpUw2ihLRZSvPd0WzeRk3tMDONFZ4QM5IIJvtshRCzawJl3o3mAzCyUuWmCcLG0tXGqzIcMFzNLD5EEYcEWaHH_iDIQJjn3yvcynE8ostPcMP-UNr5e1j",
                "id": "rs_0324062a6a56a4660169091bea2960819080f126bd1eedebff",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762204648,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 554,
        "prompt_tokens": 375,
        "total_tokens": 929,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 448,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00120175,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 9.375e-05,
          "upstream_inference_completions_cost": 0.001108
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "The targets of some antibodies are proteo-glycans. One such antibody binds MUC1, but only if the threonine within one of MUC1's repeat sequences, GSTA, carries a TN antigen, a monosacharide of N-acetylgalactosamine. \nUsing published tools, you start to put together a system to study this antibody. Your MUC1 construct carries a flag tag and is expressed on the surface of C1GALT1 KO HEK293t cells that strictly produce TN O-glycans.  You were able to show that the sugar is essential to the interaction by using inhibitory concentrations of GalNAc (500 mM), as GalNAc inhibits the antibody's ability to bind when compared to PBS controls. In addition to verifying the surface expression of MUC1, why is it essential to include the anti-flag antibody, and to which step should it be added?\n\n\nAnswer Choices:\nA. No need, controls are good\nB. Anti-flag should be added with the secondary antibodies. Its included to control for potential off-target effects of the 500 mM GalNAc.\nC. Anti-flag should be added with the primary antibodies. Its included to verify GalNAc has not altered surface expression of MUC1\nD. Anti-flag should be added with the primary antibodies. Its included to control for potential off-target effects of the 500 mM GalNAc. \nE. Anti-flag should be added with the secondary antibodies. Its included to verify GalNAc has not altered surface expression of MUC1"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762204649-A066wwrl7GblRNmRTTNu",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"C. The anti\u2011FLAG should be included at the primary antibody step to directly report MUC1 surface levels so you can confirm that 500 mM GalNAc did not reduce or remove MUC1 expression (i.e., the loss of binding is due to glycan blocking, not loss/alteration of the antigen).\",\"answer_letter\":\"C\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": null,
            "reasoning_details": [
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCRvwleYp8_vfIxPp3_TmWtYL_iNMgU0BLZPwMfsGGLJ-JY0I_6o9uSPDfGxjvFVvrWXT5ct3JHK3pFjFbzVODoYIvQmhwqIag7tqV1z499wAEpK0HGDCErMappHNxmZnM3wvkbD11SpS-43lGtrfxa9V_2zglYDiHmqkPJ2-KfwNU5M2CyHtWb_3EysDm0HVl3TOJKqe-J8mTl5YckvYVRX5KlCzdyKZKAcFNADTcxmF3gBIOeBovFKZC-IO5N7jMorlRQqMUuHDVM4xFml-MTm7zbg5sqHfbmkPR6GuyRn144025ACwDTdYA1jFOKX6ex47lomfUUV5b3wnEWjW2HfdeYFNmZgA456LORhTmwWTxZy3U7FKUvM1fRxX-8b0dtpCgPBubp_tX26VQB2xL83diKY4ZXYmn2beQMg16dBpVonfx2PP396myuJPii8FfUlA3o1FwB4rJg6Lw4RgnXIaygCq4gCS_wEsYmkNDdVt0LaG5do3ORnrJUT5MUS5mxw9IQTdWaRl-xjssf-7MVmbQ9cur48CFmkLPvKxLeqiq21RLK8J922Is66zw6iBSAGqVfiUdee2R0wdjULRcOW8gdEhkIdQp9DgZtbrn_XrQwROC27fGOm8F4CpkGxgkoiN67ecWvkNK_BDlrbxczlhAOeD-IxSQ8T2DYhop0WhQxKLHMMGkldAUGK48DQATJB_ZuiwVlKUfPnIKc-_1G45VL7TrcPah5Xd2ZjLXZEgjAIW8EfAFZIi464SHszb2sGfmcRb8ZaJckI5WtQiAea-8DQMpxTpdNlqqt_g0X6J0udgYTayeyCl3xzw9ernq91RK-b2V1gug_ZfLbAo7t0QK2DccK1G4qvuCsWslrVAH3NZ3MapLIkhsBjmjIvRmBjesfVFOesqVPFBVJ5NkEnGu_HeW1mgjBlrtTjzC2-126eaLTNL3KuSyV-rsb2AfKyhMK78BxmgqgLyH97Yw4aV9je7rWKiiYU8WFZI7eC3sprBx3bcqqKScMF1QR2x4gAm7kbqnwt2bcXhn6zaqTImWNB8PwRlbvMONl0DYf4qXdCnx_D4JAQPDQBglgamLRs_UJyqjW60FT6F3ThUceN-6bR4MLoD6lpiBu7YqOXActtZ-567u-aRvAlzGaueRw_qwATAoTN47So2loTK_rx6Wjm5dYVlm8jaZJhLC7gvdM2m5vRjRSTK6hRyFX-FgcKxklzsSN7bwS3JkBafeZSXo2p_IFVxA4AusDYy2Fu7By28LYTJF4qXBvHtATq_nDBfncln6f6UBaDIDIMuRqHkHFNx7rLJ1aHWGAR_ilLDDKPZJePpB1pyBmVuurf3717V6QqBIMlPlsDFbh03p5zkL073g1IeprsO7Ym59-VlOQ0kvj9R87LnuIWFsH4OiPcjogFDXMwTtlLQlVB-xxozTQS_oL82ZaZQ8JBSp9Vyov0siNrfSt75w6NMW7rSgPif3kudWVwM6SuKk6fXYJxQhp2ZxlQoNIWt2TPk7w5Wmvulfd0HLgCuys7m__k67OsxPWPLs2JS6Wdzyi-6MtZx5DUT6luwAmW_NuoqSVJZTBCPwts1ktaIUMrXBxUcuH2Mgoe1LiKNVb2T-hNuDSqBkIioP0en12-czKkMLEZf0T58VCYHPT-iSPzqA_TEWVUsJTw39mxYVL6mYz5tUt-9htiv9ucZP4n7pETxcT6j_Bsg2MVZin_VBrU1BabNAbxBJaXabSUQi49OI6ihbwDz2f6E1Z8qyHaFhl3TAjFQOS2nYkMBtCPAu5AOSqqQ0b1mCGt-aZuzQGURsB9P7l8sAAQIhHei9zZavzkyiK5aAEKp4SBOryZlmTrF8I6JTdR9k3C7PL4bADzp14lChHNG_rdYL8d_9F-378_AHYS8WVo2LP6OqZ2aZrkvute-18SIiAfwXlgXocy1PaOYW5yOt5laDGT-xaFpBgMmuVjrCqxd3OB8gLKEuAzYNaJti4Z0aOXG4j7kXputynOC6rH4ZLCR1iBy59v2d8ZrltGSZj6Xl0u_ysrn9Zr_X-_ZQlD0lmh8J1T8nLEw5Es7HNz1VVRz3aVdZrzS66nMES9iSoO8oELxRSXQeAGUr6FplujsfSUoYysz0YZtUDNljHm4YFJc8VGH4dThItB83BE1fqWwNYQa2sljBhGge7HqPvl5SY2Hzs0B995hxAttXUs-shqd4FJr76eYKE08NUTnz7RbGWvLsWUNUN_H0F5AnPuASrHERqFrPes3YPGNEiV50r4jprwdnTQDpswyqgRAintIn7Yca8k_bmN9Ku0imdoPN1TKuV_Yyj9IAjPmANSDaaLZpEbMtaoktV9rjdZbLjvj0AMtLAgBivbTeyr7AeR06M_K3R6f_Ix1SPrmblbKdNkmw7UFMz37j0ShYuHmZhRsBgJurwENzPv6mHxXdCnOHkokbcIgw4oRZO_SHss_IWJecFx751u-CG2eIM-uTzPHtPbjNHq8QWobpZyLtoZBFAziFaucX9GoW9F-mNEfGKzfGbgfEzFB5BLC2mH9aN9FRUXERevuLHi5758yCXXTrf8F-AfN5oOsfp4yBLOgdjaTHoWl6ZDxOfie0uJzkvwKV-79yaqPPDJsqx8wyfcC52vG6voEA-dWDXdKKSPQAW50VhdAMuk94B3FY8vOOvH3LzpL3o0BKI2IFPdwQJIowaIdrjhHEl8JvS35dhqJSptiSDyLKKpftISW-kgLGlsheyL3joRGsw8Ma1xC5lojCC0Ut3zpsc-6H7ZiQMx9Fl-UThsX_SUzwj_pcNtAXzYU-kDdXFlT7IKhK8sVAHIeVRY-LTuwYXcAridw7-FZ1d7b39Lz8oE7u_dZ33zDwaPB4FrHWJysma8Sb7U-ixHfwhDCYImv0huoR7YZcyRXq8b2GHXhBVnksGX1gOloYZQgzQQ5cPWY8BY9uyq_kTIgeHd4N34Wv5Pab5DhW93MmwoZiJXz0XtAkV2HMZwxIQjv4lxFozm9MxqvHnQ7bdBAFN1CRETkT6N4JPSG_EmMsUUmjCaWaeCL8sEPD_2E3c8Ca_F_WNmWHMh0DRw-FiygjVLiPP8NcLJlCx_Cee5_8_MXTyIiuJE3i5T1K8knsOBelPXqh_yaJhHYK7QmAtJwSgFyAKKSsvbH9u_eQNCbmcZpLSK-1qBDZ2siDClXvGzcg5P6PfFchyEIPLmszOJRFxoqwpjkwd3__XnLKv-6wq94WITGMkmbSHvCgxitl59Z-9HO8fD_-Xtifum0TnDty625xoQiaJKGpqOwWNYlKc0DSCq7eS1PCeaS2klSVyDCdhipPj01AhJQLZnsS6pOZ0B1T5ULU_yjlfd7iW-E1Axa2lNc5uzlXbeG020lljeqKWFPsNjGUFC0fWpdKel0XllwBVVbrGu-k3oBkjSeBw==",
                "id": "rs_0463853a760a51c20169091bea36bc8193bb7101e244296ae5",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762204649,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 469,
        "prompt_tokens": 375,
        "total_tokens": 844,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 384,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00103175,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 9.375e-05,
          "upstream_inference_completions_cost": 0.000938
        }
      },
      "provider": "OpenAI"
    }
  }
]